带状疱疹疫苗的免疫应答。
Immune responses to zoster vaccines.
机构信息
a Departments of Pediatrics , University of Colorado Denver School of Medicine, Anschutz Medical Campus , Aurora , CO , USA.
b Department of Medicine , University of Colorado Denver School of Medicine, Anschutz Medical Campus , Aurora , CO , USA.
出版信息
Hum Vaccin Immunother. 2019;15(4):772-777. doi: 10.1080/21645515.2018.1560918. Epub 2019 Jan 24.
Abstract
There are two licensed herpes zoster vaccines. One is a live vaccine (ZVL) based on an attenuated varicella-zoster virus (VZV). The other is a recombinant vaccine (RZV) based on the VZV glycoprotein E (gE) combined with AS01B, a multicomponent adjuvant system. RZV is superior to ZVL in efficacy, and differs from ZVL in that protection is not diminished by the age of the vaccinee and has not waned significantly during 4 years of follow-up. Immunologic studies demonstrated higher peak memory and persistence of T cell responses in RZV compared with ZVL recipients. RZV recipients also showed development and persistence of polyfunctional T cell responses. Taken together, we conclude that the immunologic data parallel and support the higher efficacy over time of RZV compared with ZVL.
摘要
有两种获得许可的带状疱疹疫苗。一种是基于减毒水痘带状疱疹病毒（VZV）的活疫苗（ZVL）。另一种是基于 VZV 糖蛋白 E（gE）与 AS01B 的重组疫苗（RZV），AS01B 是一种多组分佐剂系统。RZV 在疗效上优于 ZVL，与 ZVL 不同的是，疫苗接种者的年龄不会降低保护效果，并且在 4 年的随访中并未明显减弱。免疫研究表明，与 ZVL 受种者相比，RZV 受种者的记忆 T 细胞和持久 T 细胞反应更高。RZV 受种者还表现出多功能 T 细胞反应的发展和持续存在。综上所述，我们得出结论，免疫数据与 RZV 相对于 ZVL 的更高疗效平行且支持其更高疗效。
相似文献
1
Immune responses to zoster vaccines.
Hum Vaccin Immunother. 2019;15(4):772-777. doi: 10.1080/21645515.2018.1560918. Epub 2019 Jan 24.
2
Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.
J Virol. 2021 May 24;95(12). doi: 10.1128/JVI.00240-21.
3
The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.
J Virol. 2019 Jul 17;93(15). doi: 10.1128/JVI.00305-19. Print 2019 Aug 1.
4
Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
J Infect Dis. 2017 Dec 12;216(11):1343-1351. doi: 10.1093/infdis/jix482.
5
Predictors of 5-Year Persistence of Antibody Responses to Zoster Vaccines.
J Infect Dis. 2023 Nov 11;228(10):1367-1374. doi: 10.1093/infdis/jiad132.
6
The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.
J Infect Dis. 2021 Oct 13;224(7):1139-1146. doi: 10.1093/infdis/jiaa083.
7
Th1 memory differentiates recombinant from live herpes zoster vaccines.
J Clin Invest. 2018 Oct 1;128(10):4429-4440. doi: 10.1172/JCI121484. Epub 2018 Jul 19.
8
Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine.
Curr Opin Immunol. 2019 Aug;59:42-48. doi: 10.1016/j.coi.2019.02.009. Epub 2019 Apr 17.
9
Evaluation of glycoprotein E subunit and live attenuated varicella-zoster virus vaccines formulated with a single-strand RNA-based adjuvant.
Immun Inflamm Dis. 2020 Jun;8(2):216-227. doi: 10.1002/iid3.297. Epub 2020 Mar 13.
10
Herpes Zoster Vaccines.
J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S429-S442. doi: 10.1093/infdis/jiab387.
引用本文的文献
1
Antibody Titer Against Varicella Zoster Virus and Recombinant Varicella Zoster Vaccine in Hemodialysis Patients: What We Know, What We Should Know.
Life (Basel). 2025 Apr 7;15(4):621. doi: 10.3390/life15040621.
2
A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates.
Front Immunol. 2024 Jul 16;15:1419634. doi: 10.3389/fimmu.2024.1419634. eCollection 2024.
3
Current development of therapeutic vaccines for the treatment of chronic infectious diseases.
Clin Exp Vaccine Res. 2024 Jan;13(1):21-27. doi: 10.7774/cevr.2024.13.1.21. Epub 2024 Jan 31.
4
Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques.
Emerg Microbes Infect. 2024 Dec;13(1):2309985. doi: 10.1080/22221751.2024.2309985. Epub 2024 Feb 11.
5
Pre-Clinical Development of an Adenovirus Vector Based RSV and Shingles Vaccine Candidate.
Vaccines (Basel). 2023 Nov 2;11(11):1679. doi: 10.3390/vaccines11111679.
6
Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors.
Rheumatology (Oxford). 2024 Jul 1;63(7):2024-2033. doi: 10.1093/rheumatology/kead552.
7
Top 100 Most-Cited Papers in Herpes Zoster from 2000 to 2022: A Bibliometric Study.
J Pain Res. 2023 May 29;16:1779-1797. doi: 10.2147/JPR.S409616. eCollection 2023.
8
Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2175558. doi: 10.1080/21645515.2023.2175558. Epub 2023 Feb 13.
9
Fraternal Twins: The Enigmatic Role of the Immune System in Alphaherpesvirus Pathogenesis and Latency and Its Impacts on Vaccine Efficacy.
Viruses. 2022 Apr 21;14(5):862. doi: 10.3390/v14050862.
10
An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21.
NPJ Vaccines. 2022 Apr 22;7(1):45. doi: 10.1038/s41541-022-00467-z.
本文引用的文献
1
Herpes Zoster Vaccines.
J Infect Dis. 2018 Sep 22;218(suppl_2):S127-S133. doi: 10.1093/infdis/jiy382.
2
Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine.
J Infect Dis. 2019 Jan 7;219(2):335-338. doi: 10.1093/infdis/jiy514.
3
Th1 memory differentiates recombinant from live herpes zoster vaccines.
J Clin Invest. 2018 Oct 1;128(10):4429-4440. doi: 10.1172/JCI121484. Epub 2018 Jul 19.
4
A spliced latency-associated VZV transcript maps antisense to the viral transactivator gene 61.
Nat Commun. 2018 Mar 21;9(1):1167. doi: 10.1038/s41467-018-03569-2.
5
Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults.
Hum Vaccin Immunother. 2018 Jun 3;14(6):1370-1377. doi: 10.1080/21645515.2018.1442162. Epub 2018 Mar 21.
6
Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study.
Am J Epidemiol. 2018 Jan 1;187(1):161-169. doi: 10.1093/aje/kwx245.
7
Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
NPJ Vaccines. 2017 Sep 8;2:25. doi: 10.1038/s41541-017-0027-3. eCollection 2017.
8
Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Clin Infect Dis. 2017 Oct 1;65(7):1174-1182. doi: 10.1093/cid/cix484.
9
Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.
J Immunol. 2017 Jul 15;199(2):604-612. doi: 10.4049/jimmunol.1700290. Epub 2017 Jun 12.
10
Metabolic Phenotypes of Response to Vaccination in Humans.
Cell. 2017 May 18;169(5):862-877.e17. doi: 10.1016/j.cell.2017.04.026. Epub 2017 May 11.
Zotero 插件